Approches actuelles au traitement du zona: Aspects controversés du traitement du zona

od Bissonnette, R., Leclerc, G.
Izdano 1992

Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-γ and altered expression of Bcl-2/Bax

od Pettersson, F, Dalgleish, A G, Bissonnette, R P, Colston, K W
Izdano 2002

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

od Ports, WC, Khan, S, Lan, S, Lamba, M, Bolduc, C, Bissonnette, R, Papp, K
Izdano 2013

Immunoregulatory activity of a T-cell receptor alpha chain demonstrated by in vitro transcription and translation.

od Onda, T, Brunner, T, Messier, H, Bissonnette, R, Echeverri, F, Baier, G, Fotedar, A, Green, D R
Izdano 1995

9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation.

od Bissonnette, R P, Brunner, T, Lazarchik, S B, Yoo, N J, Boehm, M F, Green, D R, Heyman, R A
Izdano 1995

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice

od Li, Y, Zhang, Y, Hill, J, Kim, H-T, Shen, Q, Bissonnette, R P, Lamph, W W, Brown, P H
Izdano 2008

Immunoregulatory activity of the T-cell receptor alpha chain demonstrated by retroviral gene transfer.

od Green, D R, Bissonnette, R, Zheng, H G, Onda, T, Echeverri, F, Mogil, R J, Steele, J K, Voralia, M, Fotedar, A
Izdano 1991

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

od Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
izdano v J Eur Acad Dermatol Venereol (2015)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement

od Leshem, Y.A., Bissonnette, R., Paul, C., Silverberg, J.I., Irvine, A.D., Paller, A.S., Cork, M.J., Guttman‐Yassky, E.
izdano v J Eur Acad Dermatol Venereol (2019)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Stu...

od Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
izdano v J Eur Acad Dermatol Venereol (2018)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

od Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
izdano v J Eur Acad Dermatol Venereol (2015)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermati...

od Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D.J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A.B., Guttman‐Yassky, E.
izdano v Br J Dermatol (2019)